2 completed. 2 Phase 4.
| Phase | Trials | Status |
|---|---|---|
| Phase 4 | 2 | Completed 2 |
Follow Immunogenicity: new trials by email Literature Review of Immunogenicity trials Research Report on Immunogenicity
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| COVID-19 CoronaVac in Patients With Autoimmune Rheumatic Diseases and HIV/AIDS CoronaVac - Rheumatic Disease, HIV Infections | Phase 4 | Completed | University of Sao Paulo General Hospital | 2196 | 2021-02-09 | 2024-03-26 |
| Reactogenicity and Protectivity Following Measles- Rubella (MR) Routine Immunization in Indonesian Infants and Children Measles-Rubella (MR) Vaccine - Safety Issues, Immunogenicity | Phase 4 | Completed | PT Bio Farma | 590 | 2017-11-16 | 2019-09-12 |
Acquired Immunodeficiency Syndrome (1) · Arthritis, Rheumatoid (1) · COVID-19 (1) · HIV Infections (1) · Lupus Erythematosus, Systemic (1) · Rheumatic Diseases (1)
Arthritis (1) · Autoimmune Diseases (1) · Blood-Borne Infections (1) · Communicable Diseases (1) · Connective Tissue Diseases (1) · Coronaviridae Infections (1) · Coronavirus Infections (1) · Genital Diseases (1) · Immune System Diseases (1) · Immunologic Deficiency Syndromes (1) · Infections (1) · Joint Diseases (1) · Lentivirus Infections (1) · Lung Diseases (1) · Musculoskeletal Diseases (1)
Vaccines (1) · sinovac COVID-19 vaccine (1)
PT Bio Farma (1) · University of Sao Paulo General Hospital (1)
Brazil (1) · Indonesia (1)
PMID 34331051, PMID 34664616, PMID 34806342, PMID 34894235, PMID 34901885, PMID 34954325, PMID 35135832, PMID 35193873, PMID 35277389, PMID 35306594, PMID 35639644, PMID 35844042, PMID 36150668, PMID 36192386, PMID 36529052, PMID 36870351, PMID 37291679, PMID 42261247